【循環器】 AMI患者において、Selatogrelの単回皮下投与は、迅速な用量依存性の抗血小板作用を示し、忍容性も良好である可能性が示唆された。 スイスの第II相RCT。 PMID:32439008 https://t.co/ftzNVXX4dE 即効性の短時間作用型P2Y12阻害薬として期待されてますが、注射部位反応等がどうか気になる所
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
Single-dose subcutaneous administration of selatogrel in patients with #AMI was safe and induced a profound, rapid, and dose-related antiplatelet response. #CardioTwitter https://t.co/Gs93Cg4gFh
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction https://t.co/onN3oTV5ei
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
I thought we already had some P2Y12 inhibitors that achieve adequate antiplatelet effects (~40-50%) at 30 minutes...🧐
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
RT @hect2701: "Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-…
"Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-related antiplatelet response." @smexcardiologia @SOCiME_ @MinervaCardioa1 @INC_CathLab @vlgmrc @Costa_F_8 @CRT_meeting https://
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
RT @JACCJournals: Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this pr…
Oral P2Y12 receptor antagonists have slow platelet inhibition. Can a new P2Y12, selatogrel be more efficacious in this process? Dr. @vlgmrc et al. investigate in #JACC: https://t.co/OVNhMkDW05 https://t.co/r8RoCgaJ3Z
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
👀Interesting approach in acute Cardiovascular disease 👀
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction https://t.co/b89apBxOaR
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction | JACC: Journal of the American College of Cardiology https://t.co/6nLNqBEtRM
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @sbrugaletta: will be the new cangrelor? @vlgmrc @PCRonline @DFCapodanno @JACCJournals
will be the new cangrelor? @vlgmrc @PCRonline @DFCapodanno @JACCJournals
Interesting study by Prof. Peter Sinnaeve et al. Promising results.
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @vlgmrc: Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely…
Selatogrel is not only a new potent parenteral p2y12 inhibitor. Selatogrel will be investigated in the context of a completely new paradigm: the patient not the doctor will be at the center of the decision making for its administration !
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
RT @JACCJournals: Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with…
Single-dose subcutaneous administration of selatogrel safely induces a rapid P2Y12 antiplatelet response in patients with #cvMI. Learn more in the latest #JACC: https://t.co/OVNhMkDW05 @vlgmrc https://t.co/921NjDC8kC
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction | JACC: Journal of the American College of Cardiology https://t.co/h1LKL3tdSV
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction https://t.co/SYvUBR7ib6 https://t.co/HMPtKykwsn
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
RT @gonzaeperez: #SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 1…
#SELATOGREL SUBCUTANEO EN INFARTO DE MIOCARDIO Este Inh P2Y12 subcutáneo se testeo en 47 pac con #STEMI o #NSTEMI. A los 15 minutos ya había inh plaquetaria <100 PU y persistente más allá de los 60 min. Interesante fármaco 🤔 Vía @JACCJournals https://